Clinical Trial Update: ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating gefitinib (ZD-1839) in combination with chemotherapy for non-small cell lung cancer; current status is not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer | Phase 3 | Status: UNKNOWN